This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Multidisciplinary Association for Psychedelic Studies: Difference between revisions
>Unity Created page with "The '''Multidisciplinary Association for Psychedelic Studies''' ('''MAPS''') is a membership-based 501(c)(3) non-profit<ref>http://www.maps.org/images/fiscal/MAPS_IRS_Letter.p..." |
>Unity No edit summary |
||
| Line 1: | Line 1: | ||
The '''Multidisciplinary Association for Psychedelic Studies''' ('''MAPS''') is a membership-based 501(c)(3) non-profit<ref>http://www.maps.org/images/fiscal/MAPS_IRS_Letter.pdf|IRS Letter Confirming MAPS' 501(c)(3) Non-Profit Status</ref> research and educational organization working to develop medical, legal, and cultural contexts for the responsible use of [[psychedelic]] substances and [[cannabis]]. MAPS was founded in 1986 by [[Rick Doblin]] and is currently based in Santa Cruz, California.<ref>http://www.maps.org/about|MAPS - About</ref> | The '''Multidisciplinary Association for Psychedelic Studies''' ('''MAPS''') is a membership-based 501(c)(3) non-profit<ref>http://www.maps.org/images/fiscal/MAPS_IRS_Letter.pdf|IRS Letter Confirming MAPS' 501(c)(3) Non-Profit Status</ref> research and educational organization working to develop medical, legal, and cultural contexts for the responsible use of [[psychedelic]] substances and [[cannabis]]. MAPS was founded in 1986 by [[Rick Doblin]] and is currently based in Santa Cruz, California.<ref>http://www.maps.org/about|MAPS - About</ref> | ||
Among other things, MAPS helps researchers across the world design, fund, and obtain regulatory approval for studies of the safety and effectiveness of a number of currently controlled psychoactive substances, right now with a particular focus on the legalization and approval of [[MDMA]] (3,4-methylenedioxymethamphetamine) as a prescription medicine for psychedelic psychotherapy.<ref>http://www.maps.org/images/brochures/MAPS-brochure-web-Feb2015.pdf|MAPS February 2015 Web Brochure</ref> MAPS works closely with government regulatory authorities across the world including the United States [https://en.wikipedia.org/wiki/Food_and_Drug_Administration Food and Drug Administration (FDA)] and the [https://en.wikipedia.org/wiki/European_Medicines_Agency European Medicines Agency (EMEA)] to ensure that all of its sponsored research protocols conform to ethical and procedural guidelines for clinical drug research, spearheading the re-introduction of psychedelics and cannabis into mainstream society after | Among other things, MAPS helps researchers across the world design, fund, and obtain regulatory approval for studies of the safety and effectiveness of a number of currently controlled psychoactive substances, right now with a particular focus on the legalization and approval of [[MDMA]] (3,4-methylenedioxymethamphetamine) as a prescription medicine for psychedelic psychotherapy.<ref>http://www.maps.org/images/brochures/MAPS-brochure-web-Feb2015.pdf|MAPS February 2015 Web Brochure</ref> MAPS works closely with government regulatory authorities across the world including the United States [https://en.wikipedia.org/wiki/Food_and_Drug_Administration Food and Drug Administration (FDA)] and the [https://en.wikipedia.org/wiki/European_Medicines_Agency European Medicines Agency (EMEA)] to ensure that all of its sponsored research protocols conform to ethical and procedural guidelines for clinical drug research, spearheading the re-introduction of psychedelics and cannabis into mainstream society after 50+ years of prohibition. | ||
Included in MAPS’ research efforts are MDMA for the treatment of post-traumatic stress disorder (PTSD); [[LSD]] and [[psilocybin]] for the treatment of anxiety, cluster headaches, and depression associated with end-of-life issues; [[ibogaine]] for the treatment of [[opiate]] [ | Included in MAPS’ research efforts are MDMA for the treatment of post-traumatic stress disorder (PTSD); [[LSD]] and [[psilocybin]] for the treatment of anxiety, cluster headaches, and depression associated with end-of-life issues; [[ibogaine]] for the treatment of [[opiate]] [https://en.wikipedia.org/wiki/Addiction addiction], [[ayahuasca]] for the treatment of drug addiction and PTSD; [[cannabis|medical cannabis]] for PTSD; and alternative delivery systems for medical cannabis such as vaporizers and water pipes.<ref>https://en.wikipedia.org/wiki/Multidisciplinary_Association_for_Psychedelic_Studies|Multidisciplinary Association for Psychedelic Studies - Wikipedia</ref> It also recognizes, if not directly sponsors, scientific research into psychedelics such as [[ketamine]] for treating addiction, [[LSA]] for cluster headaches and general psychopharmacological research into compounds like [[MDE]], [[DMT]], and [[Salvinorin A]].<ref>http://www.maps.org/research/other-research|MAPS - Other Psychedelics Research</ref> MAPS officials say the organization's ultimate goal is to establish a network of clinics where these and other treatments can be provided together with other therapies under the guidance of trained, licensed physicians and therapists.<ref>{{cite journal |author=Doblin R |title=A clinical plan for MDMA ("Ecstasy") in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA |journal=Journal of Psychoactive Drugs |volume=34 |issue=2 |pages=185–94 |year=2002 |pmid=12691208 |doi=10.1080/02791072.2002.10399952}}</ref> | ||
In addition to sponsoring scientific research, MAPS organizes continuing medical education (CME) conferences, the most prominent of which is the "Psychedelic Science" conference which they host around April every year. Additionally, MAPS sponsors and presents lectures and seminars on the state of psychedelic and medical marijuana research, provides psychedelic [[harm reduction]] services through the Zendo Project at events such as music festivals and [https://en.wikipedia.org/wiki/Burning_Man Burning Man], and publishes a triannual magazine-style publication, the MAPS Bulletin, with updates about its ongoing research efforts, legal struggles, and educational initiatives. MAPS also publishes books dealing with the science, history, and culture of psychedelic research and [https://en.wikipedia.org/wiki/Psychedelic_therapy psychedelic therapy].<ref>https://en.wikipedia.org/wiki/Multidisciplinary_Association_for_Psychedelic_Studies|Multidisciplinary Association for Psychedelic Studies - Wikipedia</ref> | In addition to sponsoring scientific research, MAPS organizes continuing medical education (CME) conferences, the most prominent of which is the "Psychedelic Science" conference which they host around April every year. Additionally, MAPS sponsors and presents lectures and seminars on the state of psychedelic and medical marijuana research, provides psychedelic [[harm reduction]] services through the Zendo Project at events such as music festivals and [https://en.wikipedia.org/wiki/Burning_Man Burning Man], and publishes a triannual magazine-style publication, the MAPS Bulletin, with updates about its ongoing research efforts, legal struggles, and educational initiatives. MAPS also publishes books dealing with the science, history, and culture of psychedelic research and [https://en.wikipedia.org/wiki/Psychedelic_therapy psychedelic therapy].<ref>https://en.wikipedia.org/wiki/Multidisciplinary_Association_for_Psychedelic_Studies|Multidisciplinary Association for Psychedelic Studies - Wikipedia</ref> | ||
| Line 9: | Line 9: | ||
According to their mission statement, MAPS ultimately envisions a "world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits".<ref>http://www.maps.org/about/mission|MAPS - Mission</ref>. Additionally, MAPS’ harm-reduction efforts are intentionally and carefully designed to avoid backlash and "build a post-prohibition world by assisting non-medical users to transform difficult psychedelic experiences into opportunities for growth".<ref>Emerson, A., Ponté, L., Jerome, L., & Doblin, R. (2014). History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). Journal of psychoactive drugs, 46(1), 27-36.</ref> | According to their mission statement, MAPS ultimately envisions a "world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits".<ref>http://www.maps.org/about/mission|MAPS - Mission</ref>. Additionally, MAPS’ harm-reduction efforts are intentionally and carefully designed to avoid backlash and "build a post-prohibition world by assisting non-medical users to transform difficult psychedelic experiences into opportunities for growth".<ref>Emerson, A., Ponté, L., Jerome, L., & Doblin, R. (2014). History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). Journal of psychoactive drugs, 46(1), 27-36.</ref> | ||
In the psychedelic and psychonautic communities, MAPS is widely regarded with great affection and respect due to its enduring commitment to integrity, honesty, transparency and willingness to take informed, evidence-backed risks. | In the psychedelic and psychonautic communities, MAPS is widely regarded with great affection and respect due to its enduring commitment to integrity, honesty, transparency and willingness to take informed, evidence-backed risks to create radical new paradigms for the alleviation of human suffering through the judicious exploration of human consciousness. | ||
== History == | == History == | ||